Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.
Overview
CV Sciences, Inc. is a comprehensive consumer wellness company that integrates science and nature to improve overall health and well-being. Specializing in nutraceuticals and plant-based foods, the company brings together scientifically-backed hemp extracts and natural ingredients across a diverse range of products. By leveraging deep research, clinical validations, and independent testing, CV Sciences positions itself as an informed and reliable entity in the health and wellness sector.
Core Business and Strategic Focus
The core mission of CV Sciences is to make healthy people healthier. The company’s operations span the development, manufacturing, and distribution of wellness products that cater to both human and pet consumers. Its business model is anchored on the production of hemp-based supplements and plant-derived food products that are sold through multiple channels including direct-to-consumer (B2C) and business-to-business (B2B) outlets. The product portfolio is carefully developed with an emphasis on science and quality, ensuring that each offering is supported by clinical research and complies with industry safety standards.
Product Portfolio and Innovation
CV Sciences offers an expansive range of product lines that exemplify its commitment to innovation and excellence. The +PlusCBD brand, a flagship in hemp extract supplements, has earned recognition for its research-backed approach and quality assurance through clinical studies and laboratory testing. Complementing this is the Cultured Foods brand, which provides a variety of 100% plant-based foods designed to meet the nutritional demands of vegan, gluten-free, and flexitarian consumers. The company has also recently expanded into pet wellness with specialized products designed to support joint health and calming effects for companion animals, an innovation that further extends its market reach.
Quality, Research, and Safety
A major component of CV Sciences' value proposition is its dedication to quality and safety. The company was one of the first to invest in generating scientific evidence required to obtain self-affirmed Generally Recognized as Safe (GRAS) status, particularly for its hemp extract supplements. Clinical research data and published studies support product benefits, ensuring that customers receive products that are not only natural but are scientifically validated for efficacy and safety. Independent laboratory tests and adherence to Good Manufacturing Practices (GMP) further solidify the company’s commitment to producing reliable and high-quality nutraceuticals.
Market Position and Competitive Landscape
Operating in the highly competitive consumer wellness and nutraceutical space, CV Sciences has distinguished itself through its diversified product portfolio and a robust focus on scientific research. Its offerings cater to a range of consumer needs, from natural wellness supplements to innovative pet care products, allowing the company to capture multiple market segments. The breadth of its product lines, combined with strategic measures such as mergers and acquisitions, positions CV Sciences as a resilient and adaptive participant in the natural products market. Detailed market insights and trend analyses reinforce its approach, ensuring that the company maintains a competitive edge in a rapidly evolving industry.
Global Presence and Operational Excellence
With primary offices and facilities strategically located in San Diego, California, and Warsaw, Poland, CV Sciences leverages a global operational framework to optimize production and distribution channels. The company’s strategic acquisitions, including Elevated Softgels and Extract Labs, enhance its manufacturing capabilities while providing operational flexibility and cost efficiencies. This global footprint underpins its long-standing commitment to excellence, ensuring consistent quality and timely delivery of state-of-the-art wellness products to customers worldwide.
Strategic Acquisitions and Integration
The proactive pursuit of strategic acquisitions bolsters CV Sciences’ operational capacity and enriches its product innovation pipeline. By integrating companies with complementary technologies and manufacturing strengths, such as Elevated Softgels and Extract Labs, the firm has expanded its ability to produce cost-effective and high-quality encapsulated supplements and tinctures. These acquisitions not only streamline the supply chain but also provide synergistic benefits that translate into enhanced market responsiveness and broader product offerings.
Commitment to Science and Consumer Wellness
At its core, CV Sciences is driven by a mission that combines scientific rigor with natural wellness. Every segment of its operation is designed to uphold the values of transparency, quality, and reliability. Whether through the development of hemp extract-based solutions, the diversification into cannabinoid-free wellness products under the +PlusHLTH brand, or the careful formulation of pet care products, the company consistently demonstrates its dedication to consumer well-being. This scientifically-oriented approach, coupled with a commitment to continuous innovation, underscores the company’s role as an authoritative source in the wellness industry.
In summary, CV Sciences offers a well-rounded, research-informed perspective on modern health and nutrition by providing a diverse array of nutraceutical and plant-based foods. Its strategic emphasis on scientific validation and operational excellence makes it a noteworthy name for anyone seeking comprehensive and quality-driven wellness solutions.
CV Sciences (OTCQB:CVSI) reported its fiscal year 2024 results with revenue of $15.7 million, slightly down 1.9% from $16.0 million in 2023. The company's Q4 2024 revenue was $3.9 million, up 2.2% from $3.8 million in Q4 2023.
Key financial metrics include improved gross margin of 45.6% for 2024 (up from 44.3% in 2023), reduced operating expenses by 5.4% to $9.4 million, and an adjusted EBITDA loss of $0.8 million, significantly improved from a $2.3 million loss in 2023.
Notable developments include the acquisition of Elevated Softgels, launch of +PlusHLTH™ supplement line, partnership with Chewy for pet products, and introduction of Lunar Fox vegan food line. The company maintained its position as the top-selling hemp extract brand in natural product retail.
CV Sciences (OTCQB:CVSI) has launched Lunar Fox Food Co., a new line of plant-based food products targeting the growing vegan market. The product line includes seven innovative offerings: CHEDDRLY MAC! (vegan mac and cheese), CHEDDRLY! (dairy-free cheese substitute), WHISKED! (egg substitute for omelets), BAKED! (dairy-free egg alternative for baking), MANGIA! (Italian-seasoned meatless alternative), FIESTA! (Mexican-spiced meatless alternative), and BOLOGNESE! (plant-based Italian sauce).
All products are 100% natural, gluten-free, and available at select retailers and through lunarfoxfoods.com. This launch expands CV Sciences' portfolio, which includes +PlusHLTH cannabinoid-free supplements, +PlusCBD Extra Support Gummies, Reserve gummies, and pet products.
CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has scheduled its Year End and Fourth Quarter 2024 financial results announcement for March 27, 2025, before market opening.
The company will host a conference call with investors at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) on the same day. Investors can participate through a webcast available on the company's Investor Relations website or by dialing (877) 407-0784 for U.S. callers or (201) 689-8560 for international participants.
A replay of the call will be accessible until April 3, 2025, by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) with confirmation code 13752212.
CV Sciences (OTCQB:CVSI) has launched new 2.5 mg THC Fizz Tablets as part of their Aura Collection product line. The lemon-flavored, fast-acting tablets are designed to be dissolved in beverages, offering an alcohol-free alternative for relaxation and stress relief. The vegan and gluten-free tablets are made with premium hemp extract and are now available at select retailers and the company's website.
This launch follows the September 2024 introduction of the Aura Collection, which includes Serene and Illuminate Gummies combining THC and CBD. The expansion adds to CV Sciences' growing portfolio, which recently added +PlusHLTH™ cannabinoid-free supplements, +PlusCBD™ Reserve gummies, and +PlusCBD™ pet products.
CV Sciences (OTCQB:CVSI) has entered into a definitive agreement to acquire Extract Labs, a premium cannabinoid products manufacturer. The acquisition, valued at $400,000 in cash and $1,000,000 in CVSI shares at closing, includes potential additional share-based earnouts up to $600,000 based on revenue targets. Extract Labs, a GMP-certified and FDA-registered facility, offers manufacturing flexibility and efficient product development capabilities. The deal aims to increase sales, optimize operations, and enable in-house production of select +PlusCBD™ products. The transaction is expected to close in Q1 2025.
CV Sciences reported Q3 2024 financial results with revenue of $3.9 million, down 5% from Q3 2023's $4.1 million. Gross margin improved to 46.0% compared to 45.1% in Q3 2023. The company maintained a cash balance of $1.0 million and secured financing of $0.9 million from Streeterville. Notable developments include the launch of +PlusHLTH™, a cannabinoid-free supplement line, and expansion of pet product offerings. B2B sales declined 9% due to state CBD regulations. The company reported an operating loss of $0.3 million and negative adjusted EBITDA of $75,000, showing improvement from Q3 2023.
CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has announced it will release its Q3 2024 financial results on November 14, 2024, before market open. The company will host a conference call with investors at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) on the same day. The webcast will be available on the company's Investor Relations website and archived for approximately 30 days. U.S. investors can join via (877) 407-0784, while international callers can use (201) 689-8560. A replay will be available until November 21, 2024.
CV Sciences (OTCQB: CVSI) has launched +PlusHLTH, a new line of cannabinoid-free supplements designed to enhance focus, mood, energy, and metabolism. The product line includes three variations:
1. Clarity: A cognitive enhancer with DMAE, Huperzine A, Rhodiola, and Lion's Mane.
2. Peace: A stress-relief formula with Holy Basil, Lemon Balm, St. John's Wort, and L-Theanine.
3. ReShape: A metabolism and weight management supplement with Berberine, OEA, and Cinnamon.
The new products are available nationwide at select retailers and on the company's website. CEO Joseph Dowling stated that +PlusHLTH fills a growing demand for natural supplements addressing key wellness challenges, offering a cannabinoid-free alternative or complement to their CBD-based product line.
CV Sciences, Inc. (OTCQB:CVSI) reported its Q2 2024 financial results, showing stable revenue of $4.0 million, consistent with Q2 2023 and Q1 2024. The company achieved a gross margin of 47.0%, its best in 13 quarters, up from 43.3% in Q2 2023. CV Sciences maintained its position as the top-selling hemp extract brand in natural product retail sales. The company acquired Elevated Softgels and appointed Maxim Group as a financial advisor. Despite an operating loss of $0.6 million, this was an improvement from the $1.1 million loss in Q2 2023. CV Sciences reported negative adjusted EBITDA of $6,000, close to break-even, compared to $0.9 million in Q2 2023. The company's cash balance stood at $0.5 million at quarter-end, down from $1.3 million at the end of 2023.
CV Sciences (OTCQB: CVSI), a leading consumer wellness company specializing in hemp extracts and natural products, has announced its plans to release financial results for the second quarter of 2024 on Tuesday, August 13, 2024, before the stock market opens. The company will host a conference call with investors at 7:00 a.m. Pacific Time on the same day.
Investors can access the webcast through the company's Investor Relations website or directly via a provided link. For those preferring to participate by phone, U.S. callers can dial (877) 407-0784, while international callers should use (201) 689-8560. A replay of the call will be available until August 20, 2024.
FAQ
What is the current stock price of Cv Sciences (CVSI)?
What is the market cap of Cv Sciences (CVSI)?
What core business does CV Sciences focus on?
How does CV Sciences ensure product quality and safety?
What distinguishes the +PlusCBD brand?
What role do strategic acquisitions play in CV Sciences' growth?
How does CV Sciences cater to the pet wellness market?
What is CV Sciences' approach to innovation?
Which sales channels does CV Sciences use to reach its customers?
How does the company maintain its global operational efficiency?
